Erector Spinae Plane Block Versus Retrolaminar Block for Analgesia in Percutaneous Nephrolithotomy
Ultrasound-guided Erector Spinae Plane Block Versus Retrolaminar Block for Postoperative Analgesia in Patients Undergoing Percutaneous Nephrolithotomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Alexandria, Egypt, 21431
- Ahmed S.Shehab
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients scheduled for PCNL
Exclusion Criteria:
- daily consumption of analgesics
- allergy to local anesthetics
- liver dysfunction
- infection or previous surgery in the vertebral region.
- patient refusal
- pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Group I
This group will receive ultrasound-guided erector spinae plane block
|
ESPB
|
|
Experimental: Group II
This group will receive ultrasound-guided Retrolaminar plane block
|
RLB
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
measurement of visual analogue score
Time Frame: after the surgery average 48 hours postoperative
|
measurement of visual analogue score during rest and movement.
The Score range from 0-10.
0 means no pain and 10 indicates the worst pain ever
|
after the surgery average 48 hours postoperative
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
postoperative additional analgesic requirement
Time Frame: after the surgery average 48 hours postoperative
|
Total cumulative analgesic requirement dose
|
after the surgery average 48 hours postoperative
|
|
assessing the patient satisfaction by a the short assessment of patient satisfaction score (SAPS)
Time Frame: after the surgery average 48 hours postoperative
|
from 0 to 28, where 0 is so dissatisfied and 28 means very satisfied
|
after the surgery average 48 hours postoperative
|
|
Time to ambulate
Time Frame: after the surgery average 12 hours postoperative
|
Time from discharge from the operating theatre to start to ambulate
|
after the surgery average 12 hours postoperative
|
|
presence of postoperative nausea and vomiting
Time Frame: after the surgery average 48 hours postoperative
|
Number of postoperative nausea and vomiting
|
after the surgery average 48 hours postoperative
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ahmed S. Shehab, MD, Alexandria University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0306627
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.